Arbutus Biopharma Corporation (ABUS) Earns Outperform Rating from JMP Securities
Arbutus Biopharma Corporation (NASDAQ:ABUS)‘s stock had its “outperform” rating restated by JMP Securities in a research report issued on Wednesday. They presently have a $13.00 price target on the biopharmaceutical company’s stock, up from their previous price target of $12.00. JMP Securities’ target price would suggest a potential upside of 72.19% from the company’s current price.
Several other research firms have also recently issued reports on ABUS. Zacks Investment Research cut Arbutus Biopharma Corporation from a “hold” rating to a “sell” rating in a research note on Tuesday, July 4th. Chardan Capital reissued a “buy” rating on shares of Arbutus Biopharma Corporation in a report on Monday, August 7th. Wedbush restated an “outperform” rating and set a $9.00 price objective on shares of Arbutus Biopharma Corporation in a research note on Wednesday, September 20th. Finally, ValuEngine upgraded shares of Arbutus Biopharma Corporation from a “sell” rating to a “hold” rating in a research note on Thursday, September 21st. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $12.65.
Shares of Arbutus Biopharma Corporation (NASDAQ:ABUS) traded down 1.656% on Wednesday, reaching $7.425. The company had a trading volume of 253,526 shares. The stock has a 50 day moving average price of $4.98 and a 200-day moving average price of $3.87. The company’s market capitalization is $408.57 million. Arbutus Biopharma Corporation has a 12 month low of $2.35 and a 12 month high of $8.25.
ILLEGAL ACTIVITY WARNING: “Arbutus Biopharma Corporation (ABUS) Earns Outperform Rating from JMP Securities” was originally posted by Watch List News and is owned by of Watch List News. If you are accessing this story on another domain, it was stolen and republished in violation of international copyright and trademark legislation. The legal version of this story can be viewed at https://www.watchlistnews.com/arbutus-biopharma-corporation-abus-earns-outperform-rating-from-jmp-securities/1607901.html.
In other Arbutus Biopharma Corporation news, insider Michael J. Sofia sold 30,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 15th. The stock was sold at an average price of $3.70, for a total value of $111,000.00. Following the completion of the sale, the insider now directly owns 1,563,403 shares in the company, valued at $5,784,591.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 10.00% of the stock is owned by insiders.
Hedge funds and other institutional investors have recently modified their holdings of the business. Vanguard Group Inc. increased its position in shares of Arbutus Biopharma Corporation by 2.7% during the 2nd quarter. Vanguard Group Inc. now owns 77,413 shares of the biopharmaceutical company’s stock valued at $279,000 after purchasing an additional 2,035 shares during the period. OxFORD Asset Management LLP raised its stake in shares of Arbutus Biopharma Corporation by 89.9% in the 2nd quarter. OxFORD Asset Management LLP now owns 83,310 shares of the biopharmaceutical company’s stock worth $300,000 after buying an additional 39,436 shares in the last quarter. Renaissance Technologies LLC raised its stake in shares of Arbutus Biopharma Corporation by 785.1% in the 1st quarter. Renaissance Technologies LLC now owns 124,573 shares of the biopharmaceutical company’s stock worth $405,000 after buying an additional 110,499 shares in the last quarter. Victory Capital Management Inc. bought a new stake in shares of Arbutus Biopharma Corporation in the 2nd quarter worth $478,000. Finally, Bank of Montreal Can lifted its holdings in shares of Arbutus Biopharma Corporation by 1.9% in the second quarter. Bank of Montreal Can now owns 874,254 shares of the biopharmaceutical company’s stock valued at $3,147,000 after buying an additional 16,535 shares during the period. 67.04% of the stock is owned by hedge funds and other institutional investors.
Arbutus Biopharma Corporation Company Profile
Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV).
Receive News & Ratings for Arbutus Biopharma Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.